Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma

Gary A. Ulaner, Debra A. Goldman, Craig S. Sauter, Jocelyn Migliacci, Joshua Lilienstein, Mithat Gönen, Heiko Schöder, Craig Moskowitz, Andrew D. Zelenetz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma. Materials and Methods: A HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables. Results: A total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence interval [CI]: 56%, 82%) in patients without FDG-avid lesions, but only 35% (95% CI: 20%, 61%) for patients with FDG-avid lesions (P =.014). For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patients without FDG-avid lesions, but only 18% (95% CI: 5%, 64%) for patients with FDG-avid lesions (P <.0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P <.0001 to P =.01; for DSS, P <.0001 to P =.002; and for OS, P <.0001 to P =.015. Conclusion: Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

Original languageEnglish (US)
Pages (from-to)518-526
Number of pages9
JournalRadiology
Volume277
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Lymphoma
Disease-Free Survival
Survival
Confidence Intervals
Positron Emission Tomography Computed Tomography
Health Insurance Portability and Accountability Act
Research Ethics Committees
Fluorodeoxyglucose F18
Positron-Emission Tomography
Transplantation
Recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Ulaner, G. A., Goldman, D. A., Sauter, C. S., Migliacci, J., Lilienstein, J., Gönen, M., ... Zelenetz, A. D. (2015). Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma. Radiology, 277(2), 518-526. https://doi.org/10.1148/radiol.2015142556

Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma. / Ulaner, Gary A.; Goldman, Debra A.; Sauter, Craig S.; Migliacci, Jocelyn; Lilienstein, Joshua; Gönen, Mithat; Schöder, Heiko; Moskowitz, Craig; Zelenetz, Andrew D.

In: Radiology, Vol. 277, No. 2, 01.01.2015, p. 518-526.

Research output: Contribution to journalArticle

Ulaner, GA, Goldman, DA, Sauter, CS, Migliacci, J, Lilienstein, J, Gönen, M, Schöder, H, Moskowitz, C & Zelenetz, AD 2015, 'Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma', Radiology, vol. 277, no. 2, pp. 518-526. https://doi.org/10.1148/radiol.2015142556
Ulaner GA, Goldman DA, Sauter CS, Migliacci J, Lilienstein J, Gönen M et al. Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma. Radiology. 2015 Jan 1;277(2):518-526. https://doi.org/10.1148/radiol.2015142556
Ulaner, Gary A. ; Goldman, Debra A. ; Sauter, Craig S. ; Migliacci, Jocelyn ; Lilienstein, Joshua ; Gönen, Mithat ; Schöder, Heiko ; Moskowitz, Craig ; Zelenetz, Andrew D. / Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma. In: Radiology. 2015 ; Vol. 277, No. 2. pp. 518-526.
@article{e5da4598be314558804cc5294cfe08d5,
title = "Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma",
abstract = "Purpose: To determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma. Materials and Methods: A HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables. Results: A total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32{\%}) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11{\%}) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68{\%} (95{\%} confidence interval [CI]: 56{\%}, 82{\%}) in patients without FDG-avid lesions, but only 35{\%} (95{\%} CI: 20{\%}, 61{\%}) for patients with FDG-avid lesions (P =.014). For autologous SCT, the 2-year PFS was 72{\%} (95{\%} CI: 64{\%}, 82{\%}) in patients without FDG-avid lesions, but only 18{\%} (95{\%} CI: 5{\%}, 64{\%}) for patients with FDG-avid lesions (P <.0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P <.0001 to P =.01; for DSS, P <.0001 to P =.002; and for OS, P <.0001 to P =.015. Conclusion: Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.",
author = "Ulaner, {Gary A.} and Goldman, {Debra A.} and Sauter, {Craig S.} and Jocelyn Migliacci and Joshua Lilienstein and Mithat G{\"o}nen and Heiko Sch{\"o}der and Craig Moskowitz and Zelenetz, {Andrew D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1148/radiol.2015142556",
language = "English (US)",
volume = "277",
pages = "518--526",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma

AU - Ulaner, Gary A.

AU - Goldman, Debra A.

AU - Sauter, Craig S.

AU - Migliacci, Jocelyn

AU - Lilienstein, Joshua

AU - Gönen, Mithat

AU - Schöder, Heiko

AU - Moskowitz, Craig

AU - Zelenetz, Andrew D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma. Materials and Methods: A HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables. Results: A total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence interval [CI]: 56%, 82%) in patients without FDG-avid lesions, but only 35% (95% CI: 20%, 61%) for patients with FDG-avid lesions (P =.014). For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patients without FDG-avid lesions, but only 18% (95% CI: 5%, 64%) for patients with FDG-avid lesions (P <.0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P <.0001 to P =.01; for DSS, P <.0001 to P =.002; and for OS, P <.0001 to P =.015. Conclusion: Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

AB - Purpose: To determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma. Materials and Methods: A HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables. Results: A total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence interval [CI]: 56%, 82%) in patients without FDG-avid lesions, but only 35% (95% CI: 20%, 61%) for patients with FDG-avid lesions (P =.014). For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patients without FDG-avid lesions, but only 18% (95% CI: 5%, 64%) for patients with FDG-avid lesions (P <.0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P <.0001 to P =.01; for DSS, P <.0001 to P =.002; and for OS, P <.0001 to P =.015. Conclusion: Performing FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

UR - http://www.scopus.com/inward/record.url?scp=84946022874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946022874&partnerID=8YFLogxK

U2 - 10.1148/radiol.2015142556

DO - 10.1148/radiol.2015142556

M3 - Article

C2 - 26035588

AN - SCOPUS:84946022874

VL - 277

SP - 518

EP - 526

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -